Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries

Komen, J.J. and Pottegård, A. and Mantel-Teeuwisse, A.K. and Forslund, T. and Hjemdahl, P. and Wettermark, B. and Hellfritzsch, M. and Hallas, J. and Olesen, M. and Bennie, M. and Mueller, T. and Voss, A. and Schink, T. and Haug, U. and Kollhorst, B. and Karlstad, Ø. and Kjerpeseth, L.J. and Klungel, O.H. (2021) Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. EP Europace. ISSN 1099-5129

[thumbnail of Komen-etal-EPE-2021-Persistence-and-adherence-to-non-vitamin-K-antagonist-oral-anticoagulant-treatment-in-patients] Text (Komen-etal-EPE-2021-Persistence-and-adherence-to-non-vitamin-K-antagonist-oral-anticoagulant-treatment-in-patients)
Komen_etal_EPE_2021_Persistence_and_adherence_to_non_vitamin_K_antagonist_oral_anticoagulant_treatment_in_patients.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 18 March 2022.

Download (358kB) | Request a copy from the Strathclyde author

    Abstract

    Aim: To assess persistence and adherence to non-vitamin K antagonist oral anticoagulant (NOAC) treatment in patients with atrial fibrillation (AF) in five Western European healthcare settings. Methods: We conducted a multi-country observational cohort study, including 559 445 AF patients initiating NOAC therapy from Stockholm (Sweden), Denmark, Scotland, Norway, and Germany between 2011 and 2018. Patients were followed from their first prescription until they switched to a vitamin K antagonist, emigrated, died, or the end of follow-up. We measured persistence and adherence over time and defined adequate adherence as medication possession rate ≥90% among persistent patients only. Results: Overall, persistence declined to 82% after one year and to 63% after five years. When including restarters of NOAC treatment, 85% of the patients were treated with NOACs after five years. The proportion of patients with adequate adherence remained above 80% throughout follow-up. Persistence and adherence were similar between countries and was higher in patients starting treatment in later years. Both first year persistence and adherence were lower with dabigatran (persistence: 77%, adherence: 65%) compared to apixaban (86% and 75%) and rivaroxaban (83% and 75%) and were statistically lower after adjusting for patient characteristics. Adherence and persistence with dabigatran remained lower throughout follow-up. Conclusion: Persistence and adherence were high among NOAC users in five Western European healthcare settings and increased in later years. Dabigatran use was associated with slightly lower persistence and adherence compared to apixaban and rivaroxaban

    ORCID iDs

    Komen, J.J., Pottegård, A., Mantel-Teeuwisse, A.K., Forslund, T., Hjemdahl, P., Wettermark, B., Hellfritzsch, M., Hallas, J., Olesen, M., Bennie, M. ORCID logoORCID: https://orcid.org/0000-0002-4046-629X, Mueller, T. ORCID logoORCID: https://orcid.org/0000-0002-0418-4789, Voss, A., Schink, T., Haug, U., Kollhorst, B., Karlstad, Ø., Kjerpeseth, L.J. and Klungel, O.H.;